ArticleMolecular biotechnology2018
DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.
Article in Molecular biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Improving stem cell-derived extracellular vesicles for better tendon and tendon-to-bone junction regeneration: strategies and future directions.Stem cell research & therapy · 2026Review
- Review
- Exosome in HBV infection: current concepts and future perspectives.Frontiers in cellular and infection microbiology · 2025Review
- Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development.Frontiers in immunology · 2025Review
- Review
- Extracellular Vesicles in Viral Liver Diseases.Viruses · 2024Review
- Extracellular vesicle-based anti-HOXB7 CD8Cancer gene therapy · 2024Article
- A quick and innovative pipeline for producing chondrocyte-homing peptide-modified extracellular vesicles by three-dimensional dynamic culture of hADSCs spheroids to modulate the fate of remaining ear chondrocytes in the M1 macrophage-infiltrated microenvironment.Journal of nanobiotechnology · 2024Article
- Extracellular vesicles as tools and targets in therapy for diseases.Signal transduction and targeted therapy · 2024Review
- Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity andCurrent HIV research · 2024Article
- Extracellular Vesicles and Infection: From Hijacked Machinery to Therapeutic Tools.Pharmaceutics · 2023Review
- Exosomal HBV-DNA for diagnosis and treatment monitoring of chronic hepatitis B.Open life sciences · 2023Article
- The therapeutic potential of exosomes derived from different cell sources in liver diseases.American journal of physiology. Gastrointestinal and liver physiology · 2022Review
- The potential therapeutic value and application prospect of engineered exosomes in human diseases.Frontiers in cell and developmental biology · 2022Review
- A Comprehensive Insight into the Role of Exosomes in Viral Infection: Dual Faces Bearing Different Functions.Pharmaceutics · 2021Review
- Emerging Role of Nef in the Development of HIV Associated Neurological Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Review
- The C-Terminal Domain of NefVaccines · 2021Article
- Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases.Journal of gastroenterology · 2021Review
- Simultaneous CD8Vaccines · 2021Article
- Exosome-Based Vaccines: History, Current State, and Clinical Trials.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Eukaryotic cells constitutively produce nanovesicles of 50-150 nm of diameter, referred to as exosomes, upon release of the contents of multivesicular bodies (MVBs). We recently characterized a novel, exosome-based way to induce cytotoxic T lymphocyte (CTL) immunization against full-length antigens. It is based on DNA vectors expressing products of fusion between the exosome-anchoring protein Nef mutant (Nef
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.